Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Zi-Kang Luo, Qiong-Feng Chen, Xiaoqin Qu & Xiao-Yan Zhou. (2019) The Roles And Signaling Pathways Of Phosphatidylethanolamine-Binding Protein 4 In Tumors. OncoTargets and Therapy 12, pages 7685-7690.
Read now
Read now
Eric Hatterer, Leticia Barba, Nelly Noraz, Bruno Daubeuf, Jean-Pierre Aubry-Lachainaye, Benoit von der Weid, Françoise Richard, Marie Kosco-Vilbois, Walter Ferlin, Limin Shang & Vanessa Buatois. (2019) Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation. mAbs 11:2, pages 322-334.
Read now
Read now
Hani M. Babiker, Ashley E. Glode, Laurence S. Cooke & Daruka Mahadevan. (2018) Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opinion on Investigational Drugs 27:4, pages 407-412.
Read now
Read now
Jan Styczynski. (2017) Managing post-transplant lymphoproliferative disorder. Expert Opinion on Orphan Drugs 5:1, pages 19-35.
Read now
Read now
Carolyn Owen & Douglas A Stewart. (2012)
Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opinion on Biological Therapy 12:3, pages 343-351.
Read now
Read now
Junshik Hong, Sanghui Park, Jinny Park, Hyung Sun Kim, Kyung-Hee Kim, Jeong Yeal Ahn, Min Young Rim, Minkyu Jung, Sun Jin Sym, Eun Kyung Cho, Dong Bok Shin & Jae Hoon Lee. (2011) Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leukemia & Lymphoma 52:10, pages 1904-1912.
Read now
Read now
Mariam Hammadi, Jacques-Olivier Pers, Christian Berthou, Pierre Youinou & Anne Bordron. (2010) A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency. OncoTargets and Therapy 3, pages 99-109.
Read now
Read now
Theresa L Whiteside. (2010) Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opinion on Biological Therapy 10:7, pages 1019-1035.
Read now
Read now
Articles from other publishers (36)
Umesh Panwar, Mohammad Aqueel Khan, Chandrabose Selvaraj & Sanjeev Kumar Singh. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal
3
29
.
SaloniArun Samant, Chandan Kumar & Usha Pandey. (2023)
Fate of
177
Lu-CHX-A”-DTPA-Rituximab: In vitro Evaluation in Raji Cell Line
. Journal of Radiation and Cancer Research 14:1, pages 21.
Crossref
Crossref
Cristina Capuano, Chiara Pighi, Simone Battella, Davide De Federicis, Ricciarda Galandrini & Gabriella Palmieri. (2021) Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. Cancers 13:10, pages 2500.
Crossref
Crossref
Patrizia Comoli & Jan Styczynski. 2021. Post-Transplant Lymphoproliferative Disorders. Post-Transplant Lymphoproliferative Disorders
221
237
.
Weijie Zhong, Zhigang Zhu, Xin Xu, Hui Zhang, Huabao Xiong, Qingshan Li & Yaming Wei. (2019) Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
Felipe Vences-Catalán, Chiung-Chi Kuo, Ranjani Rajapaksa, Caroline Duault, Noemi Andor, Debra K. Czerwinski, Ronald Levy & Shoshana Levy. (2019) CD81 is a novel immunotherapeutic target for B cell lymphoma. Journal of Experimental Medicine 216:7, pages 1497-1508.
Crossref
Crossref
Edward C. So, Ariana Khaladj-Ghom, Yaping Ji, Julian Amin, Yang Song, Erin Burch, Hua Zhou, Haoping Sun, Shaodong Chen, Soren Bentzen, Ronna Hertzano, Xiaoyu Zhang & Scott E. Strome. (2019) NK cell expression of Tim-3: First impressions matter. Immunobiology 224:3, pages 362-370.
Crossref
Crossref
Jürgen Barth. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
489
519
.
Sean H. Lim, Kim M. Linton, Graham P. Collins, Joke Dhondt, Joshua Caddy, Liz Rossiter, Karan Vadher, Keira Fines, Laura E. Rogers, Diana Fernando, Louise Stanton, Andrew J. Davies, Peter W. M. Johnson & Gareth Griffiths. (2018) RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. Trials 19:1.
Crossref
Crossref
Joseph M. Ryan, Payal Mittal, Antoine Menoret, Julia Svedova, Jeffrey S. Wasser, Adam J. Adler & Anthony T. Vella. (2018) A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. Cancer Immunology, Immunotherapy 67:4, pages 605-613.
Crossref
Crossref
Farrukh T. Awan, Lia Gore, Lei Gao, Jyoti Sharma, Joanne Lager & Luciano J. Costa. (2016)
Phase Ib trial of the
PI
3K/
mTOR
inhibitor voxtalisib (
SAR
245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell malignancies
. British Journal of Haematology 175:1, pages 55-65.
Crossref
Crossref
Rosalba Camicia, Hans C. Winkler & Paul O. Hassa. (2015) Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Molecular Cancer 14:1.
Crossref
Crossref
Cristina Capuano, Maddalena Romanelli, Chiara Pighi, Giuseppe Cimino, Angela Rago, Rosa Molfetta, Rossella Paolini, Angela Santoni & Ricciarda Galandrini. (2015) Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells. Cancer Research 75:19, pages 4097-4108.
Crossref
Crossref
J.M. Redman, E.M. Hill, D. AlDeghaither & L.M. Weiner. (2015) Mechanisms of action of therapeutic antibodies for cancer. Molecular Immunology 67:2, pages 28-45.
Crossref
Crossref
Carolyn J. Owen & Douglas A. Stewart. (2015) Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Therapeutic Advances in Hematology 6:4, pages 161-170.
Crossref
Crossref
Xavier Thomas. (2015) Toward effective targeted therapy for the treatment of adult acute lymphoblastic leukemia. International Journal of Hematologic Oncology 4:1, pages 1-4.
Crossref
Crossref
Caroline Le Jeune & Xavier Thomas. (2015) Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. European Journal of Haematology 94:2, pages 99-108.
Crossref
Crossref
Sean H. Lim & Ronald Levy. (2014) Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. The Journal of Immunology 193:4, pages 1519-1524.
Crossref
Crossref
K C Kawabata, S Ehata, A Komuro, K Takeuchi & K Miyazono. (2012) TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20. Oncogene 32:16, pages 2096-2106.
Crossref
Crossref
Kai Wang, Yu Jiang, Weiyan Zheng, Zhiyong Liu, Hui Li, Jianzhou Lou, Meidi Gu & Xiaojian Wang. (2013) Silencing of Human Phosphatidylethanolamine-Binding Protein 4 Enhances Rituximab-Induced Death and Chemosensitization in B-Cell Lymphoma. PLoS ONE 8:2, pages e56829.
Crossref
Crossref
Marielle J. Wondergem, Josee M. Zijlstra, Madelon de Rooij, Otto J. Visser, Peter C. Huijgens & Sonja Zweegman. (2012)
Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with
90
Yttrium ibritumomab tiuxetan‐BEAM and autologous stem cell transplantation
. British Journal of Haematology 157:3, pages 395-397.
Crossref
Crossref
Daan Dierickx, Emilie Beke, Timothy Devos & André Delannoy. (2012) The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders. Medical Clinics of North America 96:3, pages 583-619.
Crossref
Crossref
Junji Koya, Atsushi Iwata, Fumihiko Nakamura, Yu Nagashima, Motoshi Ichikawa, Shoji Tsuji & Mineo Kurokawa. (2012) Fludarabine may overcome resistance to rituximab in IgM-related neuropathy. Journal of the Neurological Sciences 315:1-2, pages 150-152.
Crossref
Crossref
Lois A. Lampson. 2013. Animal Models of Brain Tumors. Animal Models of Brain Tumors
3
20
.
Jesse Popov, Anita I Kapanen, Christopher Turner, Rebecca Ng, Catherine Tucker, Gigi Chiu, Richard Klasa, Marcel B Bally & Ghania Chikh. (2011)
Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and
in vivo
activity
. Nanomedicine 6:9, pages 1575-1591.
Crossref
Crossref
Britt Nakken, Ludvig A. Munthe, Yrjö T. Konttinen, Anna Klokk Sandberg, Zoltan Szekanecz, Philip Alex & Peter Szodoray. (2011) B-cells and their targeting in rheumatoid arthritis — Current concepts and future perspectives. Autoimmunity Reviews 11:1, pages 28-34.
Crossref
Crossref
Maria J. H. Boumans, Rogier M. Thurlings, Danielle M. Gerlag, Koen Vos & Paul P. Tak. (2011) Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system. Arthritis & Rheumatism 63:11, pages 3187-3194.
Crossref
Crossref
Sean H. LimAndrew T. VaughanMargaret Ashton-Key, Emily L. WilliamsSandra V. DixonH. T. Claude ChanStephen A. BeersRuth R. FrenchKerry L. CoxAndrew J. Davies, Kathleen N. Potter, C. Ian MockridgeDavid G. Oscier, Peter W. M. Johnson, Mark S. CraggMartin J. Glennie. (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118:9, pages 2530-2540.
Crossref
Crossref
Lyudmyla Derby & Myron S Czuczman. (2011) Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future Oncology 7:8, pages 963-979.
Crossref
Crossref
Tadeusz Robak & Ewa Robak. (2011) New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies. BioDrugs 25:1, pages 13-25.
Crossref
Crossref
Nishant Tageja. (2011) Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma. Clinical Medicine Insights: Oncology 5, pages CMO.S6085.
Crossref
Crossref
Cheng Fang, Wei Xu & Jian-Yong Li. (2010) A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. Annals of Hematology 89:11, pages 1107-1113.
Crossref
Crossref
Riad Abès, Emmanuelle Gélizé, Wolf Herman Fridman & Jean-Luc Teillaud. (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116:6, pages 926-934.
Crossref
Crossref
Nishant Tageja & Jasdeepa Nagi. (2010) Bendamustine: something old, something new. Cancer Chemotherapy and Pharmacology 66:3, pages 413-423.
Crossref
Crossref
Isabel Vogler, Sebastian Newrzela, Sylvia Hartmann, Nadine Schneider, Dorothee von Laer, Ulrike Koehl & Manuel Grez. (2010) An Improved Bicistronic CD20/tCD34 Vector for Efficient Purification and In Vivo Depletion of Gene-Modified T Cells for Adoptive Immunotherapy. Molecular Therapy 18:7, pages 1330-1338.
Crossref
Crossref
Deborah A. Thomas, Susan O'Brien & Hagop M. Kantarjian. (2009) Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, pages 949-971.
Crossref
Crossref